RxDoctor Payments Data

Juan Gonzalez

Foot & Ankle Surgery · McAllen, TXNPI 1235364365

Payments from drug & device makers

$4,808in general payments, 2019–2025

Across 121 payments — averaging $39.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$2K
  • Pylant Medical$1K
  • HNM Stainless, LLC$565
  • Paratek Pharmaceuticals, Inc.$201
  • Stryker$168
  • Amniox Medical, Inc.$158
  • plus $952 from 16 others

What the payments were for

  • Food & beverage$3,60875%
  • Education$1,20025%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,808 in reported general payments places this provider in the 50th percentile of 684 foot & ankle surgery providers in Texas.

See all foot & ankle surgery providers in Texas

Medicare billing

Part B allowed, 2024
$2,982,721
Medicare patients
321
Services billed
3,349

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuzyraOmadacycline Tosylate22$187,697
Duloxetine Hcl160$3,002
Celecoxib42$1,641
Acetaminophen-CodeineAcetaminophen With Codeine145$1,090
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim164$1,051
Diclofenac Sodium15$1,030
Ibuprofen86$848
Clotrimazole24$762
Mometasone Furoate18$723
Pregabalin13$716
Ammonium Lactate34$682
Meloxicam189$638
Terbinafine Hcl45$594
Ketoconazole17$541
Clindamycin Hcl26$280

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Paratek Pharmaceuticals, Inc.Nuzyra$201$187,69722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 684 foot & ankle surgery providers in Texas.

Other foot & ankle surgery in McAllen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →